Mapp Biopharmaceutical, the biotech company responsible for the development of the experimental Ebola treatment drug, ZMapp, has reportedly developed another drug that may hold the key to ending the corruption epidemic in Africa.
The treatment, known as ZHonestegrity, was first identified as a potential cure back in 2010, but has not yet been approved for human use or completed the clinical trial process, which is standard to prove the safety and efficacy of a medication. However, the increased death rate on the continent due to the rapid spread of the corruption virus has prompted the biotech company to offer experimental treatment to a number of African leaders.
The experimental treatment programme will begin with a number of West African leaders, according to reports. Three frozen vials of the drug were flown to an undisclosed location in West Africa to be administered to presidents Jonathan Goodluck of Nigeria, John Mahama of Ghana and Yahya Jammeh of The Gambia.
Researchers from Mapp Biopharmaceutical will be monitoring to see if the three leaders show any signs of improvements.